219 related articles for article (PubMed ID: 9198248)
1. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation.
Harker LA; Hanson SR; Kelly AB
Thromb Haemost; 1997 Jul; 78(1):736-41. PubMed ID: 9198248
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic inhibition of thrombin activities, receptors, and production.
Harker LA
Hematol Oncol Clin North Am; 1998 Dec; 12(6):1211-30. PubMed ID: 9922933
[TBL] [Abstract][Full Text] [Related]
3. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
Gresele P; Momi S; Berrettini M; Nenci GG; Schwarz HP; Semeraro N; Colucci M
J Clin Invest; 1998 Feb; 101(3):667-76. PubMed ID: 9449701
[TBL] [Abstract][Full Text] [Related]
4. Blood coagulation: hemostasis and thrombin regulation.
Tanaka KA; Key NS; Levy JH
Anesth Analg; 2009 May; 108(5):1433-46. PubMed ID: 19372317
[TBL] [Abstract][Full Text] [Related]
5. Phospholipid-bound tissue factor modulates both thrombin generation and APC-mediated factor Va inactivation.
Váradi K; Siekmann J; Turecek PL; Schwarz HP; Marder VJ
Thromb Haemost; 1999 Dec; 82(6):1673-9. PubMed ID: 10613654
[TBL] [Abstract][Full Text] [Related]
6. A rationale for targeting antithrombotic therapy at the vessel wall: improved antithrombotic effect and decreased risk of bleeding.
Buchanan MR; Brister SJ
Wien Klin Wochenschr; 1999 Feb; 111(3):81-9. PubMed ID: 10093889
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model.
Suleymanov OD; Szalony JA; Salyers AK; LaChance RM; Parlow JJ; South MS; Wood RS; Nicholson NS
J Pharmacol Exp Ther; 2003 Sep; 306(3):1115-21. PubMed ID: 12829728
[TBL] [Abstract][Full Text] [Related]
8. Thrombin receptors in vascular smooth muscle cells - function and regulation by vasodilatory prostaglandins.
Schrör K; Bretschneider E; Fischer K; Fischer JW; Pape R; Rauch BH; Rosenkranz AC; Weber AA
Thromb Haemost; 2010 May; 103(5):884-90. PubMed ID: 20143010
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins.
Chesebro JH; Webster MW; Zoldhelyi P; Roche PC; Badimon L; Badimon JJ
Circulation; 1992 Dec; 86(6 Suppl):III100-10. PubMed ID: 1424043
[TBL] [Abstract][Full Text] [Related]
10. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function.
Himber J; Kirchhofer D; Riederer M; Tschopp TB; Steiner B; Roux SP
Thromb Haemost; 1997 Sep; 78(3):1142-9. PubMed ID: 9308768
[TBL] [Abstract][Full Text] [Related]
11. Differential inhibition of thrombin activity and thrombin generation by a synthetic direct thrombin inhibitor (napsagatran, Ro 46-6240) and unfractionated heparin in patients with deep vein thrombosis. ADVENT Investigators.
Bounameaux H; Ehringer H; Gast A; Hulting J; Rasche H; Rapold HJ; Reber G; Tschopp TB
Thromb Haemost; 1999 Apr; 81(4):498-501. PubMed ID: 10235427
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
Despotis GJ; Joist JH
J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
[TBL] [Abstract][Full Text] [Related]
13. Thrombin receptor antagonists as novel therapeutic targets.
Chackalamannil S
Curr Opin Drug Discov Devel; 2001 Jul; 4(4):417-27. PubMed ID: 11727307
[TBL] [Abstract][Full Text] [Related]
14. Current perspectives in the treatment of thrombotic disorders.
Drouet L; Caen JP
Semin Thromb Hemost; 1989 Apr; 15(2):111-22. PubMed ID: 2665082
[TBL] [Abstract][Full Text] [Related]
15. Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting.
Poston RS; White C; Gu J; Brown J; Gammie J; Pierson RN; Lee A; Connerney I; Avari T; Christenson R; Tandry U; Griffith BP
Ann Thorac Surg; 2006 Jan; 81(1):104-10; discussion 110-1. PubMed ID: 16368345
[TBL] [Abstract][Full Text] [Related]
16. Targeting tissue factor as an antithrombotic strategy.
Golino P; Cimmino G
Semin Vasc Med; 2003 May; 3(2):205-14. PubMed ID: 15199484
[TBL] [Abstract][Full Text] [Related]
17. [Interaction of blood and the vascular wall: hemostatic aspects].
Gerlach E; Becker BF
Z Kardiol; 1993; 82 Suppl 5():13-21. PubMed ID: 8154153
[TBL] [Abstract][Full Text] [Related]
18. Thrombin and protease-activated receptors (PARs) in atherothrombosis.
Martorell L; Martínez-González J; Rodríguez C; Gentile M; Calvayrac O; Badimon L
Thromb Haemost; 2008 Feb; 99(2):305-15. PubMed ID: 18278179
[TBL] [Abstract][Full Text] [Related]
19. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
20. Prevention of cardiovascular events after acute coronary syndrome.
Wallentin L
Semin Vasc Med; 2005 Aug; 5(3):293-300. PubMed ID: 16123917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
